Zacks Investment Research
09 Jul 2026, 19:26 UTC · 2h ago
Should You Retain CAH Stock After Removal From Several Russell Indices?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
09 Jul 2026, 19:26 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The company's Pharmaceutical and Specialty Solutions segment is delivering double-digit revenue and profit growth. — Consistent double-digit growth in core and high-margin segments drives long-term earnings expectations upward.
+0.40Cardinal Health (CAH) is being removed from the Russell 1000 Defensive, Russell 1000 Growth-Defensive, and Russell 1000 Value-Defensive indices. — Removal from major indices typically triggers automatic selling from index-tracking funds, creating short-term downward price pressure.
-0.30Cardinal Health's removal from these indices is a technical result of significant share price appreciation rather than a deterioration of business fundamentals. — Clarifying that the sell-off is technical and not fundamental helps mitigate panic and supports a long-term bullish thesis.
+0.20Continue reading
6 related stories
Top 1 mover · tap to explore
Cardinal Health's stock has risen over 70% in 2025 and an additional 15.4% year-to-date, significantly outperforming its industry and the S&P 500. — Strong momentum and relative strength indicate robust investor confidence and operational success.
+0.20Which stocks this story touches
Strong share price appreciation, outperforming the S&P 500 and industry, with a constructive long-term investment case despite technical index removal.
Mentioned as one of the three dominant U.S. pharmaceutical distributors in a growing sector.
Mentioned as one of the three dominant U.S. pharmaceutical distributors in a growing sector.
[mutual] Cardinal Health is identified as one of the three dominant U.S. pharmaceutical distributors alongside Cencora.
[mutual] Cardinal Health is identified as one of the three dominant U.S. pharmaceutical distributors alongside McKesson.
[mutual] McKesson and Cencora are identified as two of the three dominant U.S. pharmaceutical distributors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
26m ago
